Full Text
Cost-Utility Analysis Of Alemtuzumab Versus Natalizumab For The Treatment Of Relapsing-Remitting Multiple Sclerosis- Us Payer Perspective

Abstract

Authors

A Smith L Hashemi I Ma

Back to Volume 19, Issue 7
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×